Inari
PrivateLast Round
Series G
Jan 7, 2025
Est. Valuation
$2.17B
Total Funding Raised
$813M
Company Overview
Inari is an agricultural biotechnology company that develops gene-edited seeds for major row crops using a proprietary SEEDesign platform that combines AI-powered predictive design and multiplex gene editing.
Sector
Frontier & Industrial Tech
Verticals
Biotechnology, Sustainable Materials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inari Comparables
Compare Inari with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tropic Biosciences | 77% | |
| Pairwise | 77% | |
| Cibus, Inc. | 76% |
Inari Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series G | Jan 7, 2025 | ||||
| Series F | Jan 30, 2024 | ||||
| Series E | Oct 4, 2022 | ||||
| Debt | Oct 4, 2022 | ||||
| Series D | May 12, 2021 | ||||
Debt | Apr 22, 2020 |
Key People
Founding team and executive leadership
Inari Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investment Corporation of Dubai | Series C, Series D |
| CPP Investments | Series F, Series E |
| Sage Hill Investors | Series E |
| Sage Hill Capital | Series E |
| EDBI | Series C |
| State of Michigan Retirement System | Series G, Series F |
| Acre Venture Partners | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 4, 2026
Named 'AgTech Company of the Year' by AgTech Breakthrough.
- Mar 25, 2026
Named to TIME's list of America's Top GreenTech Companies 2026.
Recent news
Latest coverage and updates
- has_issues_withOct 2, 2026
Corteva accused Inari of improperly accessing patented seed materials from depositories in Delaware, an allegation resolved through a confidential settlement on Sep 28th '26.
- has_issues_withSep 29, 2026
Corteva and Inari settled a lawsuit accusing Inari of improperly obtaining Corteva’s patented seed materials, genetically modifying them, and seeking to commercialize the resulting products; Inari must destroy related biological materials and assign Corteva intellectual property associated with edited versions.
Inari Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Inari's valuation, stock price, and market status.
Is Inari a public or private company?
Inari is a private company.
What is the current stock price of Inari?
Inari is a private company, so its shares have no public market price. Caplight tracks Inari's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inari worth (valuation)?
Inari's valuation is estimated at $2.2B based on funding round data.
Can I buy Inari stock?
Inari shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inari's last funding round?
Inari's most recent funding round was Series G on January 7, 2025.
Who are the main investors in Inari?
Key investors in Inari include CPP Investments, Flagship Pioneering, K2 HealthVentures.
Will Inari IPO soon?
No public IPO plans have been announced for Inari.
How can I track Inari secondary market activity?
Caplight tracks bids, offers, and trades in Inari's shares on secondary markets.